NCT05109559View on ClinicalTrials.gov

Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

690

Participants

Timeline

Start Date

December 20, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
SARS-CoV-2 Infection
Interventions
BIOLOGICAL

Full dose of Ad26.COV2. 5x10^10vp

A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.

BIOLOGICAL

Half dose of Ad26.COV2. 2.5x10^10vp

A booster dose (3rd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.

BIOLOGICAL

Full dose of Ad26.COV2. 5x10^10vp

A booster dose (2nd dose) of Ad26.COV2.S as an IM injection in the deltoid muscle in adults.

Trial Locations (1)

10400

RECRUITING

Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi,, Bangkok

Sponsors

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

National Vaccine Institute, Thailand

OTHER

collaborator

International Vaccine Institute

OTHER

collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

Mahidol University

OTHER

NCT05109559 - Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine | Biotech Hunter | Biotech Hunter